Editas Medicine Inc (EDIT NASDAQ) stock market data APIs
$2.7155
-0.04(-1.5%)
as of November 4, 2026
Try our APIs with
free plan!
Editas Medicine Inc Financial Data Overview
Price chart is built with
Anychart
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Prev. Close
2.7155
Open
2.6798
High
2.7863
Low
2.6174
52 wk Range
1.66-3.94
Market Cap
399 M
Shares Outstanding
154 M
Revenue
47 005 K
Beta
2.077
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Editas Medicine Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Editas Medicine Inc data using free add-ons & libraries
Get Editas Medicine Inc Fundamental Data
Editas Medicine Inc Fundamental data includes:
- Net Revenue: 47 005 K
- EBITDA: -81 035 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-09
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Editas Medicine Inc News
New
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
Company Logo Key players include Beam Therapeutics, Twist Bioscience, Sangamo, Editas Medicine and Tessera Therapeutics. Profiles cover gene-writing technologies, products, applications, trends and c...
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Editas Medicine EDIT announced that it has received approval to initiate the first-in-human phase I/II Strive clinical study of EDIT-401, its investigational in vivo gene-editing candidate for heteroz...
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Editas upgraded at Wells Fargo as Australia approves gene editing trial
[Genetic engineeering concept] PhonlamaiPhoto/iStock via Getty Images Editas Medicine (EDIT [https://seekingalpha.com/symbol/EDIT]) traded higher on Thursday after Australian authorities cleared a Ph...
Get Editas Medicine Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.